Study of Paridiprubart for moderate to severe ARDS
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called paridiprubart to see if it can help people with moderate or severe acute respiratory distress syndrome (ARDS), a serious lung condition. It may be an option if you have low oxygen levels and no known allergy to the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate or severe ARDS, meaning your oxygen levels are very low.
- You do not have a known allergy to paridiprubart or ingredients like polysorbate 80.
- You do not have severe liver damage (cirrhosis with a score of 12 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests a drug called vilobelimab for people with moderate or severe ARDS (a serious lung condition). It aims to find if this treatment can help improve breathing and outcomes.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
This trial tests a drug called aprotinin for people with moderate to severe ARDS who are on a breathing machine. The goal is to see if it helps treat the lung injury.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
Hear when a new ARDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.